Related Experiment Videos
[PTHrP and breast cancer]
A Devys1, A Lortholary, M Audran
1Centre Paul-Papin, 2, rue Moll, 49033 Angers Cedex 01. a.devys@unimedia.fr
Bulletin Du Cancer
|December 14, 2001
Summary
Parathyroid hormone-related peptide (PTHrP) drives hypercalcemia in malignancy and promotes bone metastasis. Targeting PTHrP may offer new therapeutic strategies for cancer patients with bone involvement.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Context:
- Parathyroid hormone-related peptide (PTHrP) shares homology with parathyroid hormone (PTH) and acts through common and specific receptors.
- PTHrP has local autocrine/paracrine functions in normal tissues and endocrine actions on bone and kidney.
- It plays a critical role in embryonic development, growth regulation, and cellular differentiation.
Purpose:
- To elucidate the multifaceted roles of PTHrP in physiological processes and disease pathogenesis.
- To highlight PTHrP's significant contribution to humoral hypercalcemia of malignancy and bone metastasis.
- To explore the feedback loop between tumor cells and the bone microenvironment involving PTHrP and TGF-beta.
Summary:
- PTHrP is a key mediator of humoral hypercalcemia in malignancy, with elevated levels found in most patients with solid tumors.
- In breast cancer, high PTHrP expression correlates with invasive phenotypes and bone metastasis development.
- PTHrP induces osteolysis, promoting tumor progression and contributing to the autocrine regulation of tumor growth, particularly in bone metastases.
Impact:
- Understanding PTHrP's role is crucial for diagnosing and managing hypercalcemia of malignancy.
- Identifying PTHrP as a mediator in bone metastasis opens avenues for targeted therapies.
- The discovered feedback loop involving PTHrP and TGF-beta offers insights into cancer's interaction with the bone microenvironment.